147 related articles for article (PubMed ID: 30884464)
1. Rapid pleural effusion after discontinuation of lenvatinib in a patient with pleural metastasis from thyroid cancer.
Uchida T; Yamaguchi H; Nagamine K; Yonekawa T; Nakamura E; Shibata N; Kawano F; Asada Y; Nakazato M
Endocrinol Diabetes Metab Case Rep; 2019 Mar; 2019():. PubMed ID: 30884464
[TBL] [Abstract][Full Text] [Related]
2. Anaplastic thyroid carcinoma diagnosed after treatment of lenvatinib for papillary thyroid carcinoma.
Yamazaki H; Iwasaki H; Suganuma N; Toda S; Masudo K; Nakayama H; Rino Y; Masuda M
Endocrinol Diabetes Metab Case Rep; 2019 Oct; 2019():. PubMed ID: 31600721
[TBL] [Abstract][Full Text] [Related]
3. Hyperthyroidism due to thyrotropin receptor antibody stimulation of metastatic thyroid carcinoma during lenvatinib treatment: a case report.
Toda S; Kadoya M; Matsui A; Murayama D; Iwasaki H
Ann Palliat Med; 2022 Nov; 11(11):3571-3577. PubMed ID: 35726194
[TBL] [Abstract][Full Text] [Related]
4. Nasogastric administration of lenvatinib solution in a mechanically ventilated patient with rapidly growing anaplastic thyroid cancer.
Kawano F; Yonekawa T; Yamaguchi H; Shibata N; Tashiro K; Ikenoue M; Munakata S; Higuchi K; Tanaka H; Sato Y; Hosokawa A; Takeno S; Nakamura K; Nanashima A
Endocrinol Diabetes Metab Case Rep; 2020 Aug; 2020():. PubMed ID: 32755964
[TBL] [Abstract][Full Text] [Related]
5. Rapid disease progression after discontinuation of lenvatinib in thyroid cancer.
Yamazaki H; Sugino K; Matsuzu K; Masaki C; Akaishi J; Hames K; Tomoda C; Suzuki A; Uruno T; Ohkuwa K; Kitagawa W; Nagahama M; Masuda M; Ito K
Medicine (Baltimore); 2020 Mar; 99(11):e19408. PubMed ID: 32176066
[TBL] [Abstract][Full Text] [Related]
6. Gastrointestinal perforation related to lenvatinib, an anti-angiogenic inhibitor that targets multiple receptor tyrosine kinases, in a patient with metastatic thyroid cancer.
Date E; Okamoto K; Fumita S; Kaneda H
Invest New Drugs; 2018 Apr; 36(2):350-353. PubMed ID: 29018997
[TBL] [Abstract][Full Text] [Related]
7. Increased Thyroid-Hormone Requirements Consistent With Type 3 Deiodinase Induction Related to Ibrutinib in a Thyroidectomized Woman.
Mazori AY; Skamagas M
AACE Clin Case Rep; 2021; 7(2):121-123. PubMed ID: 34095468
[TBL] [Abstract][Full Text] [Related]
8. Anaplastic transformation of papillary thyroid carcinoma in multiple lung metastases presenting with a malignant pleural effusion: a case report.
Abe T; Suzuki M; Shimizu K; Shinagawa N; Oizumi S; Matsuno Y; Miyazaki M; Tanino M; Tanaka S; Nishimura M
J Med Case Rep; 2014 Dec; 8():460. PubMed ID: 25532447
[TBL] [Abstract][Full Text] [Related]
9. Common carotid artery rupture during treatment with lenvatinib for anaplastic thyroid cancer.
Obata K; Sugitani I; Ebina A; Sugiura Y; Toda K; Takahashi S; Kawabata K
Int Cancer Conf J; 2016 Oct; 5(4):197-201. PubMed ID: 31149454
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of lung metastasis-related finding in lenvatinib treatment for differentiated thyroid cancer.
Yamazaki H; Iwasaki H; Masudo K; Toda S; Matsui A; Rino Y
Endocrine; 2022 Dec; 78(3):543-551. PubMed ID: 36070050
[TBL] [Abstract][Full Text] [Related]
11. Safety of Tyrosine Kinase Inhibitors in Patients With Differentiated Thyroid Cancer: Real-World Use of Lenvatinib and Sorafenib in Korea.
Kim SY; Kim SM; Chang H; Kim BW; Lee YS; Chang HS; Park CS
Front Endocrinol (Lausanne); 2019; 10():384. PubMed ID: 31244783
[No Abstract] [Full Text] [Related]
12. Successful recovery from a subclavicular ulcer caused by lenvatinib for thyroid cancer: a case report.
Kitamura M; Hayashi T; Suzuki C; Hirano S; Tateya I; Kishimoto Y; Omori K
World J Surg Oncol; 2017 Jan; 15(1):24. PubMed ID: 28088233
[TBL] [Abstract][Full Text] [Related]
13. Response to Lenvatinib in Children with Papillary Thyroid Carcinoma.
Mahajan P; Dawrant J; Kheradpour A; Quintanilla NM; Lopez ME; Orth RC; Athanassaki I; Venkatramani R
Thyroid; 2018 Nov; 28(11):1450-1454. PubMed ID: 30226445
[TBL] [Abstract][Full Text] [Related]
14. [18F]-FDG-PET/CT Correlates With the Response of Radiorefractory Thyroid Cancer to Lenvatinib and Patient Survival.
Valerio L; Guidoccio F; Giani C; Tardelli E; Puccini G; Puleo L; Minaldi E; Boni G; Elisei R; Volterrani D
J Clin Endocrinol Metab; 2021 Jul; 106(8):2355-2366. PubMed ID: 33901285
[TBL] [Abstract][Full Text] [Related]
15. Lenvatinib for Anaplastic Thyroid Cancer and Lenvatinib-Induced Thyroid Dysfunction.
Koyama S; Miyake N; Fujiwara K; Morisaki T; Fukuhara T; Kitano H; Takeuchi H
Eur Thyroid J; 2018 Jun; 7(3):139-144. PubMed ID: 30023346
[TBL] [Abstract][Full Text] [Related]
16. Lenvatinib rechallenge in a patient with advanced thymic carcinoma: A case report.
Terashima Y; Hakozaki T; Takeuchi S; Hosomi Y
Thorac Cancer; 2022 Dec; 13(23):3408-3411. PubMed ID: 36251511
[TBL] [Abstract][Full Text] [Related]
17. Safety and Effectiveness of Lenvatinib in 594 Patients with Unresectable Thyroid Cancer in an All-Case Post-Marketing Observational Study in Japan.
Takahashi S; Tahara M; Ito K; Tori M; Kiyota N; Yoshida K; Sakata Y; Yoshida A
Adv Ther; 2020 Sep; 37(9):3850-3862. PubMed ID: 32676927
[TBL] [Abstract][Full Text] [Related]
18. Anaplastic Thyroid Carcinoma Treated with Lenvatinib.
Ohkubo JI; Takahashi A; Ikezaki S; Takenaga F; Ohkubo Y; Suzuki H
Kurume Med J; 2018 Feb; 64(1.2):29-33. PubMed ID: 29057760
[TBL] [Abstract][Full Text] [Related]
19. Rechallenge with Lenvatinib after Refractoriness to Initial Lenvatinib Followed by Sorafenib in a Patient with Metastatic Papillary Thyroid Carcinoma.
Takinami M; Yokota T
Case Rep Oncol; 2020; 13(2):522-527. PubMed ID: 32518548
[TBL] [Abstract][Full Text] [Related]
20. A Case of Squamous Cell Carcinoma of Unknown Primary that Responded to the Multi-Tyrosine Kinase Inhibitor Lenvatinib.
Kimura-Tsuchiya R; Sasaki E; Nakamura I; Suzuki S; Kawana S; Okouchi C; Fukushima T; Hashimoto Y; Suzuki S; Saji S
Case Rep Oncol; 2018; 11(1):75-80. PubMed ID: 29515414
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
